Mass Spectrometry of New Serotonin Transporter Inhibitors.

<u>Janina Witowska-Jarosz</u>^a, Jerzy Kossakowski ^b, Gabriel Nowak ^{d,e}, Andrzej J. Bojarski ^d, Karol Wołosewicz ^f, Mari Gabrielsen ^c, Ingebrigt Sylte ^c, Piotr Baran ^a, Aleksander P. Mazurek ^a, Zdzisław Chilmonczyk ^a

^a National Medicines Institute, Chelmska 30/34, 00-725 Warszawa

^b Department of Medical Chemistry, Faculty of Medicine,
Warsaw Medical Uniwersity, Oczki 3, 02-007 Warszawa

^c Molecular Modelling Group, Department of Medical Pharmacology and Toxicology, Institute of Medical Biology, Faculty of Health Sciences, University of Tromsø, Norway

^d Institute of Pharmacology, Polish Academy of Sciences, Smętna 12, 31-343 Kraków ^e Department of Pharmacobiology, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków

f Institute of Chemistry, University of Bialystok, Al. Pilsudskiego 11/4, 15-443 Bialystok e-mail: witowska@il.waw.pl, janinawj@gmail.com

The serotonin (5-HT) transporter (SERT) is the main molecular target for the selective serotonin reuptake inhibitors (SSRIs), currently the most prescribed antidepressant drugs. We obtained several new potential SERT and 5-HT $_{1A}$ receptor ligands of the general formula **1**. The compounds were evaluated in SERT affinity tests and appeared to possess high (nanomolar) affinity to SERT.

$$O_2N$$
 N
 N
 N
 N
 N

We examined a fragmentation of some new SSRI's (active in *in vitro* and *in vivo* tests) in MS sources and found exceptional stability of negative ions.

This study was supported by a grant PNRF-103-AI-1/07 through the Norwegian Financial Mechanism.